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BrainOxysterols and cholestenoic acids are oxidised forms of cholesterol with a host of biological functions.
The possible roles of oxysterols in various neurological diseases makes the analysis of these metabolites
in the central nervous system of particular interest. Here, we report the identiﬁcation and quantiﬁcation
of a panel of twelve sterols in mouse cerebrospinal ﬂuid (CSF) using liquid chromatography–mass spec-
trometry exploiting enzyme assisted derivatisation for sterol analysis technology. We found low levels of
oxysterols and cholestenoic acids in CSF in the range of 5 pg/mL–2.6 ng/mL. As found in man, these con-
centrations are one to two orders of magnitude lower than in plasma.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Oxysterols and cholestenoic acids are formed from cholesterol
as intermediates in the synthesis of bile acids and steroid hor-
mones. Oxidation of cholesterol is catalysed by numerous sterol
hydroxylases, primarily members of the cytochrome P450 (CYP)
family of enzymes [1]. Although the presence of oxysterols in
mammalian circulation has been known for many years, recent
studies have led to a renewed interest in these metabolites as they
have been shown to possess potent biological activities. For exam-
ple, 24S,25-epoxycholesterol is a ligand to the liver X receptors
(LXRs) [2], 7a,25-dihydroxcholesterol (7a,25-diHC) plays a rolein immune cell migration by binding to the Epstein-Barr virus
induced gene 2 (EBI2) [3,4], and (25R)26-hydroxycholesterol (26-
HC) has been shown to inﬂuence tumour growth by modulating
the estrogen receptor b (ERb) [5,6]. Note, here we use the system-
atic nomenclature where addition of a hydroxy group on the term-
inal carbon of the cholesterol side-chain introducing R
stereochemistry at C-25, is at C-26 giving (25R)26-hydroxycholes-
terol. The common, but systematically incorrect, name for this
molecule is 27-hydroxycholesterol [7,8].
The high level of cholesterol in the brain (approximately 2% wet
weight of brain) has stimulated research investigating altered
cholesterol metabolism as a causative factor in neurological dis-
eases. For example, oxysterol levels have been shown to be per-
turbed in neurodegenerative diseases including Alzheimer’s
disease [9] and Parkinson’s disease [10], while altered metabolism
of 25-HC has been linked to neuroinﬂammation in mouse models
[11]. Recently, it has been demonstrated that oxysterols promote
midbrain neurogenesis [12] while cholestenoic acids regulate the
survival of motor neurons both in vitro and in vivo [13].
Mousemodels of neurological diseases are an important resource
to investigate the causes and treatments of these conditions.
Increasingly sophisticated mouse models for numerous diseases
are becoming available, aswell as knockout animalswithmutations
of speciﬁc enzymes involved in sterol homeostasis. To link observed
biological phenomena to theunderlyingmolecular causes it is useful
to analyse the levels of oxysterols and cholestenoic acids in different
tissues of the mouse. Blood plasma is often used for analysis as it is
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throughout the body. However, the presence of the blood brain bar-
rier (BBB) raises questions of the relevance of plasmameasurements
in the context of neurological diseases. Previouslywe have analysed
brain tissue which circumvents this problem and allows direct
analysis of metabolites that may play a role in disease [14]. While
this is a powerful approach, translation tohumanstudies is onlypos-
sible for post mortem analysis.
An alternative is to measure oxysterols in cerebrospinal ﬂuid
(CSF). This has the advantage of relatively straightforward sample
collection in humans while representing conditions in the central
nervous system (CNS) more faithfully than blood plasma. We have
previously reported the identiﬁcation and quantitation of about 25
oxysterols and cholestenoic acids in human CSF [15] and shown
that inborn errors of cholesterol metabolism affect the levels of
the metabolites present [13]. However, to the best of our knowl-
edge, there have been no reports of the oxysterol proﬁle of mouse
CSF which makes comparisons between human diseases and
mouse models difﬁcult.
Here,wepresent a robustmethod for the identiﬁcationandquan-
tiﬁcation of cholesterol metabolites in mouse CSF that opens new
possibilities for biomarker discovery and investigations into the
underlying causes of neurological diseases. We compare this data
with concentrations of oxysterols and cholestenoic acids found in
plasma to give an overview of cholesterol metabolism in mouse.2. Experimental
2.1. Sample collection
CSF was from male (40 g) and female (34 g) Swiss/Webster
mice (4–6 months), sedated with an overdose of Nembutal
(150 lg/g body weight). CSF was collected from the cisterna magna
as described by Liu and Duff [16] but only a single sampling of 5–
10 lL was performed and the mouse was subsequently sacriﬁced.
Care was taken to avoid blood vessels when penetrating the dura
mater. Pools of 100 lL CSF for male mice and 54 lL CSF for female
mice were made. Mice were bred in the animal housing facility of
the KU Leuven, had ad libitum access to water and standard rodent
food, and were kept on a 12 h light and dark cycle. All animal
experiments were performed in accordance with the ‘‘Guidelines
for Care and Use of Experimental Animals’’ and fully approved by
the Research Advisory Committee (Research Ethical committee)
of the KU Leuven. Male mouse (B6, 3 months of age) plasma was
purchased from Jackson Laboratories (Maine, USA).
2.2. Analysis of oxysterols and cholestenoic acids
Oxysterols and cholestenoic acids from mouse plasma were
analysed using enzyme assisted derivatisation for sterol analysis
(EADSA) and liquid chromatography–tandem mass spectrometry
(LC–MSn) by the method previously described [17]. Metabolites
from mouse CSF were analysed using a similar method, but with
the modiﬁcations described below.
2.3. Extraction of oxysterols and cholestenoic acids from mouse CSF
CSF (54–100 lL)was added to ethanol (1.05 mL, Fisher Scientiﬁc)
containing 24R/S-[25,26,26,26,27,27,27-2H7]hydroxycholesterol
([2H7]24R/S-HC) (2 ng), 22R-[25,26,26,26,27,27,27-2H7]hydroxyc-
holest-4-en-3-one ([2H7]22R-HCO) (2 ng), 7a,25-[26,26,26,27,27,
27-2H6]dihydroxycholesterol ([2H6]7a,25-diHC) (0.2 ng) and
[25,26,26,26,27,27,27-2H7]cholesterol (20 lg) (all Avanti Polar
Lipids) in an ultrasound bath. After 5 min water (Fisher Scientiﬁc)
was added to give a ﬁnal volume of 1.5 mL of 70% ethanol. Themixture was centrifuged for 30 min at 17,089g at 4 C. To remove
cholesterol from the sample a solid phase extraction (SPE) step
was used. A 200 mg tC18 Sep-Pak cartridge (Waters) was pre-
conditioned with ethanol (4 mL) followed by 70% ethanol (6 mL)
afterwhich the samplewas loaded. Theﬂow-throughwas combined
with a wash of 70% ethanol (5.5 mL) to give a 7 mL fraction contain-
ing oxysterols and cholestenoic acids. The solventwas evaporated in
a vacuum centrifuge overnight.
2.4. Enzyme assisted derivatisation of oxysterols and cholestenoic
acids
The dried sample was dissolved in propan-2-ol (50 lL, Fisher
Scientiﬁc) and 50 mM KH2PO4 buffer (500 lL) then treated with
3 lL of cholesterol oxidase (2 mg/mL in H2O, 44 units/mg protein,
Sigma–Aldrich) and incubated for 1 h at 37 C. The reaction was
quenched by addition of methanol (1 mL) followed by glacial acetic
acid (75 lL, VWR) and Girard P (GP, TCI Europe) reagent (75 mg).
After vortexing, the mixture was incubated at room temperature
in the dark overnight.
Excess reagent was removed by SPE using a 50 mg tC18 Sep-Pak
cartridge (Waters) preconditioned with methanol (1.5 mL, Fisher
Scientiﬁc), 10% methanol (1.5 mL) and 70% methanol (1 mL). The
sample was loaded and allowed to ﬂow through the cartridge. To
ensure full recovery of all analytes of interest, a recycling proce-
dure was used where the eluate was diluted with an equal volume
of water and reapplied to the column. This procedure was repeated
to give a ﬁnal concentration of 17% methanol. The cartridge was
then washed with 10% methanol (1.5 mL) and the analytes of inter-
est eluted with methanol (3  250 lL to give Fr-1, Fr-2 and Fr-3)
followed by ethanol (250 lL to give Fr-4). The solvent was evapo-
rated from combined Fr-1 and Fr-2 using a vacuum centrifuge and
the sample was re-suspended in 60% methanol (100 lL) for analy-
sis by LC–MSn.
2.5. LC–MSn on the LTQ-Orbitrap
Oxysterols were separated using a RSLC nano Ultimate 3000
(Dionex) with a Hypersil Gold C18 column (1.9 lm particle size,
50  2.1 mm, Thermo Fisher). Mobile phase A consisted of 33.3%
methanol, 16.7% acetonitrile (Fisher Scientiﬁc), 50% water, contain-
ing 0.1% formic acid (VWR) while mobile phase B was 63.3%metha-
nol, 31.7% acetonitrile, 5% water, containing 0.1% formic acid. The
gradient started at 20% mobile phase B for 1 min before increasing
to 80%mobile phase B over 7 min. After holding for 5 min the gradi-
ent returned to 20% B over 6 s before re-equilibration for 3 min 54 s
to give a total run time of 17 min. The ﬂow rate was 200 lL/min and
the eluent was directed to the atmospheric pressure ionisation
source of an LTQ-Orbitrap Velos (Thermo Fisher). Eighty ﬁve micro-
litre of the derivatised mouse CSF was injected and a full scan was
performed in the Orbitrap across the m/z range 400–610 at 30,000
resolution (full width at half maximum height). At the same time
the linear ion trap (LIT) monitored MSn transitions for GP tagged
oxysterols and cholestenoic acids. Initial activationgavea character-
istic [M-79]+ fragment in MS2 corresponding to the loss of pyridine,
the [M-79]+ ionwas isolated andwhen activated further gave struc-
turally informative MS3 spectra.3. Results and discussion
3.1. Analysis using EADSA reveals 12 oxysterols and cholestenoic acids
in mouse CSF
We used EADSA to charge-tag sterols of interest with the GP
reagent (Fig. 1). Enzymatic oxidation of the characteristic sterol
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reagent which introduces a permanent positive charge to the ana-
lyte of interest in the form of a quaternary ammonium ion. This
greatly enhances analyte signal allowing the detection of low
levels of oxysterols in biological matrices. By including isotopically
labelled internal standards quantiﬁcation can be carried out with
high accuracy and reproducibility [17,18].
To account for the very low levels of oxysterols (pg/mL) in
mouse CSF, as well as the small amount of ﬂuid available (5–
10 lL per animal), we used pooled CSF samples (6–8 mice) and
made several modiﬁcations to our procedure usually employed
for plasma analysis. We used a smaller SPE cartridge (50 mg of sor-
bent cf. 200 mg for plasma) for the removal of the excess derivati-
sation reagent. In addition, before analysis we concentrated
samples in a vacuum centrifuge to maximize the amount of analyte
injected on the LC column. We worked up 100 lL of CSF pooled
frommale mice, and 54 lL of CSF pooled from females and injected
85% of each in a single injection.
Using the LTQ-Orbitrap Velos we recorded high resolution accu-
rate mass spectra with an m/z error of <5 ppm. By plotting recon-
structed ion chromatograms (RICs) for m/z values corresponding
to different oxysterols, we could detect multiple metabolites. For
example, a RIC for m/z 534.4054 shows the side-chain
monohydroxycholesterols 24S-HC, 25-HC and 26-HC along with
the B-ring oxidised metabolites 7a-HC, 7b-HC, 7-oxocholesterol
(7-OC) and 6-HC (Fig. 2). Similarly, a RIC for m/z 548.3847 shows
3b-hydroxycholest-5-enoic acid (3b-HCA, Fig. 2), while a RIC of
m/z 564.3796 shows 3b,7a-dihydroxycholest-5-enoic acid (3b,7a-
diHCA) plus 7a-hydroxy-3-oxocholest-4-enoic acid (7aH,3O-CA)
(Fig. 2). Note, using the EADSA methodology the sterol 3b-hydroxy
group is oxidised to a 3-oxo group prior to GP derivatisation (Fig. 1)
and sterols naturally possessing a 3-oxo group are differentiated
from those modiﬁed to contain one by repeating the derivatisation
reaction, with a differentially isotopically labelled GP reagent, in
the absence of prior oxidation. Due to low levels of analytes and
the scarcity of mouse CSF there was insufﬁcient material to allow
a repeat analysis so the values reported are the sum of the 3b-hy-
droxy and 3-oxo forms. Only analytes with a 7a-hydroxy group are
substrates for the endogenous hydroxysteroid dehydrogenase
enzyme HSD3B7 which in mouse oxidises the 3b-hydroxy group
to a 3-oxo group in vivo. Thus, only metabolites with a 7a-hydroxy[M-79]+
Fig. 1. Numbering of the cholesterol backbone and outline of the EAgroup can exist in a 3b and 3-oxo form in vivo (Table 1). In addition
to monohydroxycholesterols the dihydroxy metabolites 7a,24-
diHC plus 7a,24-dihydroxycholest-4-en-3-one (7a,24-diHCO),
7a,25-diHC plus 7a,25-diHCO and 7a,26-diHC plus 7a,26-diHCO
were also identiﬁed (Fig. 2).
Further conﬁrmation of the identity of the metabolites was pro-
vided by MSn spectra recorded in the LIT of the LTQ-Orbitrap.
Fragmentation of sterols tagged with the GP reagent gives a char-
acteristic peak at [M-79]+ corresponding to the loss of pyridine
(Fig. 1). Isolation of this fragment and further activation (i.e. MS3)
then gives structurally informative fragments unique to each
individual metabolite. For example, Fig. 3A shows the MS3 spec-
trum of 24S-HC with fragments characteristic of a GP derivatised
sterol, without a 7-hydroxy group present, at m/z 151.1, 163.1
and 177.1 along with compound speciﬁc fragments such as the dis-
tinctive peak at m/z 353.4. The major peak at m/z 437 corresponds
to [M-79-H2O]. Other oxysterols and cholestenoic acids give differ-
ent fragmentation patterns that can be compared with authentic
standards to conﬁrm the identity of each metabolite (Fig. 3).
By basing identiﬁcation on LC retention time, accurate mass,
and unique fragmentation patterns, we were able to detect 12
oxysterols and cholestenoic acids in mouse CSF (Table 1).
3.2. CSF concentrations of oxysterols are low in CSF in comparison to
plasma, but 7a,24-diHC plus 7a,24-diHCO is only found in CSF
By comparison of the peak areas from RICs for each metabolite
with those of deuterated internal standards we were able to quan-
tify oxysterols and cholestenoic acids in mouse CSF. For compar-
ison, we also analysed the oxysterol content of mouse plasma
using our previously reported method. The levels of oxysterols
and cholestenoic acids in mouse CSF are in the range of 5 pg/mL–
2.6 ng/mL (Table 1). These are low concentrations in the context
of levels present in mouse plasma where the range is from 0.4 to
28 ng/mL. In general, the level of each sterol is one to two orders
of magnitude higher in plasma than CSF. The most abundant
metabolites in both matrices are 3b,7a-diHCA plus 7aH,3O-CA at
a concentration of about 2.5 ng/mL in CSF and 28 ng/mL in plasma.
There is now a considerable body of evidence to indicate that
7aH,3O-CA and probably its precursor 3b,7a-diHCA are synthe-
sised in brain from 26-HC, and that brain represents the likely[M]+
DSA strategy exempliﬁed by 24S-HC. CHO: cholesterol oxidase.
Fig. 2. Oxysterols and cholestenoic acids in mouse CSF. (A) RIC form/z 534.4054 showing 24S-HC, 25-HC, 26-HC and B-ring oxidised sterols. (B) RIC form/z 550.4003 showing
7a,25-diHC/7a,25-diHCO, 7a,24-diHC/7a,24-diHCO, and 7a,26-diHC/7a,26-diHCO. (C) RIC for m/z 548.3847 showing 3b-HCA. (D) RIC for m/z 564.3796 showing 3b,7a-
diHCA/7aH,3O-CA. Note that sterols derivatised with the GP reagent form a mixture of syn and anti isomers which may or may not be resolved e.g. 3b,7a-diHCA/7aH,3O-CA
elute as syn and anti isomers at 5.77 and 6.61 min, and the second isomer of 7a,24-diHC/7a,24-diHCO elutes at 6.61 min.
Table 1
Oxysterols and cholestenoic acids identiﬁed and quantiﬁed in mouse CSF and plasma using EADSA. Mean plasma values are from 6 male B6 mice. Mean CSF values are for pooled
samples from 6 to 8 Swiss/Webster mice.
After EADSA Originating structure CSF Male
ng/mL
(nmol/L)
CSF
Female
ng/mL
(nmol/L)
Plasma
ng/mL
(nmol/L)
[M]+ m/z Formula Sterol systematic name Sterol systematic name (common name)
534.4054 C34H52N3O2+ 24S-Hydroxycholest-4-en-3-one
3-GP
Cholest-5-ene-3b,24S-diol (24S-hydroxycholesterol) 0.093
(0.230)
0.092
(0.229)
5.834
(14.500)
534.4054 C34H52N3O2+ 25-Hydroxycholest-4-en-3-one 3-
GP
Cholest-5-ene-3b,25-diol (25-hydroxycholesterol) 0.005
(0.012)
N.D. 1.216
(3.022)
534.4054 C34H52N3O2+ 26-Hydroxycholest-4-en-3-one 3-
GP
Cholest-5-ene-3b,26-diol ((25R)26-Hydroxycholesterol) 0.029
(0.073)
N.D. 8.364
(20.788)
534.4054 C34H52N3O2+ 7b-Hydroxycholest-4-en-3-one 3-
GP
Cholest-5-ene-3b,7b-diol (7b-Hydroxycholesterol) 0.137
(0.340)
N.D. 1.364
(3.390)
534.4054 C34H52N3O2+ 3b-Hydroxycholest-5-en-7-one 7-
GP
3b-Hydroxycholest-5-en-7-one (7-Oxocholesterol) 0.449
(1.116)
1.063
(2.642)
2.450
(6.089)
534.4054 C34H52N3O2+ 7a-Hydroxycholest-4-en-3-one 3-
GP
7a-Hydroxycholest-4-en-3-one or Cholest-5-ene-3b,7a-diol
(7a-Hydroxycholesterol)
0.347
(0.862)
0.182
(0.452)
25.036
(62.224)
534.4054 C34H52N3O2+ 6-Hydroxycholest-4-en-3-one 3-
GP
Cholest-4-ene-3b,6-diol or Cholest-5-ene-3b,6-diol (6-
Hydroxycholesterol)
0.677
(1.683)
0.638
(1.586)
1.466
(3.643)
548.3847 C34H50N3O3+ 3-Oxocholest-4-en-26-oic acid 3-
GP
3b-Hydroxycholest-5-en-26-oic acid 0.149
(0.357)
0.228
(0.548)
4.702
(11.294)
550.4003 C34H52N3O3+ 7a,24-Dihydroxycholest-4-en-3-
one 3-GP
7a,24-Dihydroxycholest-4-en-3-one or Cholest-5-ene-
3b,7a,24-triol
0.056
(0.134)
0.028
(0.067)
N.D.
550.4003 C34H52N3O3+ 7a,25-Dihydroxycholest-4-en-3-
one 3-GP
7a,25-Dihydroxycholest-4-en-3-one or Cholest-5-ene-
3b,7a,25-triol
0.044
(0.105)
0.033
(0.079)
0.491
(1.174)
550.4003 C34H52N3O3+ 7a,26-Dihydroxycholest-4-en-3-
one 3-GP
7a,26-Dihydroxycholest-4-en-3-one or Cholest-5-ene-
3b,7a,26-triol
0.012
(0.028)
0.010
(0.025)
0.438
(1.047)
564.3796 C34H50N3O4+ 7a-Hydroxy-3-oxocholest-4-en-
26-oic acid 3-GP
7a-Hydroxy-3-oxocholest-4-en-26-oic acid or 3b,7a-
Dihydroxycholest-5-en-26-oic acid
2.465
(5.703)
2.560
(5.921)
28.068
(83.687)
P.J. Crick et al. / Steroids 99 (2015) 172–177 175
Fig. 3. MS3 fragmentation patterns for oxysterols and cholestenoic acids in mouse CSF. (A) MS3 spectrum for the transition 534.4? 455.4? recorded at 7.41 min showing
24S-HC. Note the characteristic fragment atm/z 353.4. (B) MS3 spectrum for the transition 550.4? 471.4? recorded at 5.52 min showing 7a,25-diHC/7a,25-diHCO. (C) MS3
spectrum for the transition 564.4? 485.4? recorded at 5.79 min showing 3b,7a-diHCA/7aH,3O-CA.
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plasma is also likely to be extrahepatic and to represent a mode of
reverse cholesterol transport to liver [21]. 7a,24-diHC plus 7a,24-
diHCO is identiﬁed in CSF but not in plasma. 7a,24-diHC can be
formed from 24S-HC through 7a-hydroxylation by the enzyme
CYP39A1, however, it is not known if CYP39A1 is expressed in
brain [1]. Oxysterol 7a-hydroxylase (CYP7B1) is known to be
expressed in brain [1] and may have some activity towards 24S-
HC, thus this enzyme could also be responsible for 7a-hydrox-
ylation of 24S-HC in CNS. 24S-HC is synthesised in brain and is pre-
sent at high levels (15–50 ng/mg) [15]. There are only small
differences in the CSF oxysterol concentrations between male
and female mice and it is unknown how the patterns of these
important molecules change with age and with mouse strain.
This may be the subject of future studies as it is known that the
pattern of oxysterols in the newborn mouse is different from that
of the adult [14].
A point to consider when performing CSF analysis is the possi-
ble contamination of the sample by blood during CSF collection. If
CSF was contaminated by blood the expected ratio of 26-HC to
24S-HC in plasma and CSF would be similar. However the ratios
are quite different, the plasma ratio of 26-HC to 24S-HC is about
3/2, while in CSF it is about 1/3. This data would argue against
appreciable contamination of CSF with blood.
We have previously reported the detailed oxysterol and choles-
tenoic acid proﬁles of human plasma and CSF [13,15]. The levels of
oxysterols and cholestenoic acids in human CSF are in some cases
5–10 times higher than in mouse, with a range of 26 pg/mL–25 ng/
mL in human [13]. Similarly, the concentrations found in human
plasma are higher than in mouse ranging from about 1 to
100 ng/mL in human.4. Conclusions
LC–MS with EADSA technology allows detection and quan-
tiﬁcation of the extremely low levels of sterols found in mouse
CSF which are about 1–2 orders of magnitude lower than in mouse
plasma. A similar large difference is seen in man, reﬂecting the lim-
ited transport through the BBB. Also for other protein-bound lipids
(e.g. long chain fatty acids) [22], such differences between serum
and CSF levels have been described. These ﬁnding have to be con-
sidered when studying the effect of steroids on neuronal cells. The
analysis of oxysterols and cholestenoic acids in mouse CSF offers
new opportunities for biomarker discovery suitable for translation
to human studies.Acknowledgements
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